Exchange: NYSE·Updated 01:38 PM EDT
ABT logo

ABTAbbott Laboratories

$100.26
$0.31
(0.31%)
Today
Reported EarningsJul 16
Mkt Cap$175.17B
Vol3.89M
News
all
press releases
Boston Scientific's Q2 Earnings Coming Up: Buy, Hold or Sell the Stock?
BSX faces Q2 results with growth expected in key businesses, but lowered full-year guidance, cost pressures and weak stock performance cloud the outlook.
Zacks
More News
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks
ABT Q2 Earnings Call Flags Stronger Second-Half Setup
Abbott's raised 2026 earnings outlook and four growth drivers point to a faster second half across nutrition, devices, diagnostics and diabetes care.
Zacks
These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results
Abbott Laboratories (NYSE:ABT) reported strong Q2 results, raising its full-year earnings outlook. Analysts have a positive outlook on ABT stock.read more...
Benzinga
Stock Market News for July 17, 2026
Wall Street closed lower on Thursday, dragged down by technology stocks, as investors assessed second-quarter earnings and a batch of economic data.
Zacks
Nasdaq Tumbles 1.5% Amid Selloff In Chip Stocks: Investor Sentiment Weakens, Greed Index Moves To 'Fear' Zone
Market sentiment declined as stocks fell, with tech stocks leading the way. UnitedHealth Group and Abbott Laboratories reported strong earnings.read more...
Benzinga
Thursday's ETF Movers: IHI, PTF
In trading on Thursday, the iShares U.S. Medical Devices ETF is outperforming other ETFs, up about 5% on the day. Components of that ETF showing particular strength include shares of Abbott Laboratories, up about 11.7% and shares of Tandem Diabetes Care, up about 8.2% on the da...
Nasdaq News: Markets
Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market
ABT tops Q2 earnings and revenue estimates and lifts 2026 EPS guidance, while Medical Devices and Cancer Diagnostics fuel growth despite Nutrition weakness.
Zacks
Abbott Laboratories Reports Q2 2026 Results: Full Earnings Call Transcript
Abbott Laboratories (NYSE:ABT) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcriptsread more...
Benzinga
Abbott Laboratories, AtaiBeckley, ManpowerGroup And Other Big Stocks Moving Higher On Thursday
U.S. stocks mixed, Nasdaq falls 150 points. Abbott Labs beats Q2 estimates and raises guidance, stock jumps 12.1%. Other big gainers include ATAI, MAN, DSGR, CDNA, MAAS, HELP, RHI, SMG, FWRD, UNH, JBHT.read more...
Benzinga
<
1
2
...
>

Advertisement|Remove ads.